TY - JOUR
T1 - Breaking the malignant triangle in glioblastoma - ErbB1/nucleoin/Ras
AU - Schokoroy, Sari Trangle
AU - Goldshmit, Yona
AU - Kloog, Yoel
AU - Pinkas-Kramarski, Ronit
PY - 2014
Y1 - 2014
N2 - Glioblastoma is one of the most malignant tumors in humans, with poor diagnosis and a low survival rate. These tumors overexpress the ErbB1 receptor and have high levels of cell surface nucleolin, which serves as an indicator for disease grade. We have previously identified a crosstalk between three oncogenes: ErbB1, Ras and nucleolin. This lead us to suggest a combined treatment using FTS, to target Ras protein, and GroA, to target cell surface nucleolin, in order to break this malignant synergy. Here we review our recent findings and suggest a model explaining drugs activities:inhibition of Ras using FTS mainly reduces cell viability and motility and inhibition of nucleolin using GroA reduces the cell proliferation. The combined treatment has a more pronounced effect on glioblastoma growth.
AB - Glioblastoma is one of the most malignant tumors in humans, with poor diagnosis and a low survival rate. These tumors overexpress the ErbB1 receptor and have high levels of cell surface nucleolin, which serves as an indicator for disease grade. We have previously identified a crosstalk between three oncogenes: ErbB1, Ras and nucleolin. This lead us to suggest a combined treatment using FTS, to target Ras protein, and GroA, to target cell surface nucleolin, in order to break this malignant synergy. Here we review our recent findings and suggest a model explaining drugs activities:inhibition of Ras using FTS mainly reduces cell viability and motility and inhibition of nucleolin using GroA reduces the cell proliferation. The combined treatment has a more pronounced effect on glioblastoma growth.
M3 - مقالة
SN - 2331-0928
VL - 1
JO - Cancer Cell & Microenvironment
JF - Cancer Cell & Microenvironment
M1 - e420
ER -